Evidence map›Paper›PMID 38969721›Full record

ArticleNature methods2024

Proteome-scale tagging and functional screening in mammalian cells by ORFtag.

Filip Nemčko, Moritz Himmelsbach, Vincent Loubiere, Ramesh Yelagandula, Michaela Pagani, Nina Fasching, Julius Brennecke, Ulrich Elling, Alexander Stark, Stefan L Ameres

Abstract read
In one paragraph

Article in Nature methods, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A pooled image-based CRISPR screen identifies EAF1 as abioRxiv : the preprint server for biology · 2026
    Article
  2. Human Synthetic Biology and Programmable Gene Regulation Control.Annual review of genomics and human genetics · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Filip Nemčko *Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID http://orcid.org/0000-0002-0588-6846
Moritz Himmelsbach *Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0009-0004-4454-7259
Vincent LoubiereResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID http://orcid.org/0000-0002-3632-378X
Ramesh YelagandulaInstitute of Molecular Biotechnology (IMBA), Vienna BioCenter (VBC), Vienna, Austria.ORCID http://orcid.org/0000-0001-7418-4322
Michaela PaganiResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Nina FaschingInstitute of Molecular Biotechnology (IMBA), Vienna BioCenter (VBC), Vienna, Austria.
Julius BrenneckeInstitute of Molecular Biotechnology (IMBA), Vienna BioCenter (VBC), Vienna, Austria. julius.brennecke@imba.oeaw.ac.at.ORCID http://orcid.org/0000-0002-5141-0814
Ulrich EllingInstitute of Molecular Biotechnology (IMBA), Vienna BioCenter (VBC), Vienna, Austria. ulrich.elling@imba.oeaw.ac.at.ORCID http://orcid.org/0000-0002-4514-2809
Alexander StarkResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria. stark@starklab.org.ORCID http://orcid.org/0000-0003-2611-0841
Stefan L AmeresMax Perutz Laboratories, Vienna BioCenter (VBC), Vienna, Austria. stefan.ameres@univie.ac.at.ORCID http://orcid.org/0000-0002-8248-3098

Funding

Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) 10.55776/P29613Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) 10.55776/P33157EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) ERC-2015-CoG-682181Human Frontier Science Program (HFSP) LT000926/2020Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency) FO999902549
6 · The paper itself

Abstract

The systematic determination of protein function is a key goal of modern biology, but remains challenging with current approaches. Here we present ORFtag, a versatile, cost-effective and highly efficient method for the massively parallel tagging and functional interrogation of proteins at the proteome scale. ORFtag uses retroviral vectors bearing a promoter, peptide tag and splice donor to generate fusions between the tag and endogenous open reading frames (ORFs). We demonstrate the utility of ORFtag through functional screens for transcriptional activators, repressors and posttranscriptional regulators in mouse embryonic stem cells. Each screen recovers known and identifies new regulators, including long ORFs inaccessible by other methods. Among other hits, we find that Zfp574 is a highly selective transcriptional activator and that oncogenic fusions often function as transactivators.

Indexed as

Open Reading FramesProteomeAnimalsHumansMiceMouse Embryonic Stem CellsProteomicsProteome

Identifiers

PMID38969721
PMCPMC11399080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.